This article is more than 5 years old. Information may no longer be current.
New FDA-approved PPI now available in the US
Click Here to Manage Email Alerts
RedHill Biopharma Ltd. received exclusive rights to promote its FDA-approved esomeprazole strontium delayed-release capsules to gastroenterologists in select territories in the United States, according to a press release.
Esomeprazole strontium delayed-release (DR) capsules 49.3 mg is a prescription proton pump inhibitor developed to treat GERD in adults and reduce the risk for NSAID-associated gastric ulcer, duodenal ulcer recurrence and pathological hypersecretory conditions, per the release.
Specifically, RedHill’s DR capsules are indicated for the short-term treatment (4-8 weeks) of heartburn and other symptoms associated with GERD and/or in healing and symptomatic resolution of erosive esophagitis, and to reduce the risk for stomach ulcers in some people taking NSAIDs, according to the release.
“We are excited to promote a third GI specialty commercial product and to offer patients an additional therapeutic option. Esomeprazole strontium DR capsules 49.3 mg complements RedHill’s rapidly growing U.S. GI specialty commercial product portfolio,” Craig Miller, RedHill’s vice president of U.S. business operations and market access, said in the press release. “RedHill is pursuing additional commercial opportunities in the specialty GI area to further expand its commercial presence in the U.S.”
Disclosures: Miller is an employee of RedHill.